A Phase II Pharmacokinetic and Efficacy Study of Nordihydroguaiaretic Acid (NDGA) [masoprocol] in Non-Metastatic Recurrent Prostate Cancer
Phase of Trial: Phase II
Latest Information Update: 31 Dec 2014
At a glance
- Drugs Masoprocol (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 08 Apr 2014 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 20 Mar 2012 Actual patient number is 12 according to ClinicalTrials.gov.